Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response

Cytokine

Volumn 56, Issue 3, 2011, Pages 850-854

  Maria Grazia, Zenti ^a,b   Claudia, Stefanutti ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atherosclerosis; Cytokines; Heparin induced Extracorporeal LDL precipitation; Inflammation; LDL apheresis

Indexed keywords

APOLIPOPROTEIN B100; AUTOANTIBODY; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; MICONAZOLE NITRATE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN;

ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; BLOOD RHEOLOGY; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; CYTOKINE RESPONSE; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; LIPID OXIDATION; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CHEMICAL PRECIPITATION; DYSLIPIDEMIAS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL;

EID: 81455154390     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.08.038     Document Type: Review

References (52)

1. Libby P., Okamoto Y., Rocha V.Z., Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010, 74(2):213-220.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Weber C., Zernecke A., Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008, 8:802-815.
4. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
5. LaRosa J.C. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001, 88:291-293.
6. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001, 21:3-5.
7. Barlic J., Zhang Y., Foley J.F., Murphy P.M. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation 2006, 114:807-819.
8. Han K.H., Ryu J., Hong K.H., Ko J., Pak Y.K., Kim J.B., et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005, 111:1439-1447.
9. Blanco-Colio L.M., Martín-Ventura J.L., de Teresa E., Farsang C., Gaw A., Gensini G., et al. ACTFAST investigators: elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on inflammatory markers study: a substudy of achieve cholesterol targets fast with atorvastatin stratified titration. Am Heart 2007, 153:881-888.
10. McNeill E., Channon K.M., Greaves D.R. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci (Lond) 2010, 118(11):641-655. [Review].
11. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167:1-13.
12. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255.
13. Stefanutti C., D'Alessandri G., Russi G., De Silvestro G., Zenti M.G., Marson P., et al. Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atherosclerosis Suppl 2009, 10(5):89-94.
14. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically-elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
15. Craig W.Y., Neveux L.M., Palomaki G.E., Cleveland M.M., Haddow J.E. Lipoprotein(a) as a risk factor for ischaemic heart disease: metaanalysis of prospective studies. Clin Chem 1998, 44:2301-2306.
16. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102(10):1082-1085.
17. Amstrong V.M., Cremer P., Eberle E., Manke A., Schulze F., Wieland H., et al. The association between serum Lp(a) concentration and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986, 62:249-257.
18. Moriarty P.M. LDL-apheresis therapy: current therapeutic practice and potential future use. Future Lipidol 2006, 1(3):299-308.
19. Eisenhauser T., Armstrong V.W., Wieland H., Fuchs C., Scheler F., Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH. First clinical application of the H.E.L.P.-system. Klin Wochenschr 1987, 65:161-168.
20. Schuff-Werner P., Gohlke H., Bartmann U. The HELP/LDLapheresis multicentre study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest 1994, 24:724-732.
21. Richter W.O., Donner M.G., Hofling B., Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998, 47:863-868.
22. Xue J., Dong Q., Han X., You H., Gu Y., Lin S. Effects of HELP therapy on acute ischemic stroke and vascular endothelial cell function. Ther Apher Dial 2007, 11:171-176.
23. Jaeger B.R., Bengel F.M., Odaka K., Uberfuhr P., Labarrere C.A., Bengsch S., et al. Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long term heart transplant survivors using positron emission tomography. J Heart Lung Transplant 2005, 2:2022-2030.
24. Ramunni A., Quaranta N., Saliani M.T., Fallacara R.A., Ria R., Ranieri G. Does a reduction of adhesion molecules by LDL-apheresis have a role in the treatment of sudden hearing loss?. Ther Apher Dial 2006, 10(3):282-286.
25. Bianchin G., Russi G.P., Romano N., Fioravanti P. Treatment with HELP-apheresis in patients suffering from sudden sensorineural hearing loss: a prospective, randomized, controlled study. Laringoscope 2010, 120:800-880.
26. Ramunni A., Giancipoli G., Saracino A., Guerriero S., Saliani M.T., Gentile M.C., et al. LDL-apheresis in acute anterior ischemic optic neuropathy. Int J Artif Organs 2004, 27(4):337-341.
27. Samtleben W., Boos K.S., Fraunberger P., Briegel J., Haller M., Arendt R., et al. H.E.L.P. in gram-negative, refractory septic shock: first clinical experience. Jpn J Apher 1997, 16:91-96.
28. Bengsch S., Boos K.S., Nagel D., Seidel D., Inthorn D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 2005, 23(6):494-500.
29. Boos K.S., Trautwein A., Seidel D., Morsch G. Endotoxin removal in septicaemia using the HELP-system: first in vitro results (Abstract). Artif Organs 1995, 10:1041.
30. Old L.J. Tumor necrosis factor (TNF). Science 1985, 230:630-632.
31. Vassali P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992, 10:411-452.
32. Kapadia S.R., Oral H., Lee J., Nakamo M., Taffet G.E., Mann D.L. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ Res 1997, 81:187-195.
33. Kelly R.A., Smith T.W. Cytokines and cardiac contractile function. Circulation 1997, 95:778-781.
34. Kanda T., Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004, 45:183-193.
35. Ikeda U., Ito T., Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 2001, 24:701-704.
36. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma levels of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998, 31:391-398.
37. Munger M.A., Johnson B., Amber I.J., Callahan K.S., Gilbert E.M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723-727.
38. Biasucci L.M., Liuzzo G., Fantuzzi G., Caligiuri G., Rebuzzi A.G., Ginnetti F., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999, 99:2079-2084.
39. Krieglstein C.F., Granger D.N. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001, 14:44-54.
40. Wang Y., Blessing F., Walli A.K., Uberfuhr P., Fraunberger P., Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
41. Pfohl M., Naoumova R.P., Klass C., Knisel W., Jakober B., Risler T., et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 1994, 35:1946-1955.
42. Kroon A.A., Aengevaeren W.R., van der Werf T., Uijen G.J., Reiber J.H., Bruschke A.V., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93(10):1826-1835.
43. Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997, 38:2071-2078.
44. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998, 82:1489-1495.
45. Mason J.C. Statins and their role in vascular protection. Clin Sci 2003, 105:251-266.
46. Naoumova R.P., Thompson G.R., Soutar A.K. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004, 15:413-422.
47. Hemphill L.C. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol 2010, 4:346-349.
48. Stefanutti C., Vivenzio A., Di Giacomo S., Mazzarella B., Bosco G., Berni A. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with LDL apheresis. Transfusion 2009, 49(7):1461-1470.
49. Rovers C., Netea M.G., De Bont N., Demacker P.N.M., Jacobs C., Kullberg B.J., et al. LPS-induced cytokine production and expression of b2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis 1998, 141:99-105.
50. Grundy S.M., Cleeman J.I., Merz N.B., Brewer H.B., Clark L.T., Hunninghake D.B., et al. For the Coordinating Committee of the National Cholesterol Education Program endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
51. Schamberger B.M., Geiss H.C., Ritter M.M., Schwandt P., Parhofer K.G. Influence of LDL-apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J Lipid Res 2000, 41(5):727-733.
52. Zhang B., Maeda N., Okada K., Tatsukawa M., Sawayama Y., Matsunaga A., et al. Association between fast-migrating low-density lipoprotein subfraction as characterized by capillary isotachophoresis and intima-media thickness of carotid artery. Atherosclerosis 2006, 187(1):205-212.